The efficacy and hyperthermic release of doxorubicin from liposomal doxorubicin hydrochloride in rabbit VX2 tumours

References

• Seynhaeve AL, Dicheva BM, Hoving S, Koning GA, ten Hagen TL. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: Evaluated by in vitro/in vivo live cell imaging. J Control Release 2013;172:330–40
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010;7:653–64
   PubMed Web of Science ®Google Scholar
• Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 2011;153:198–205
   PubMed Web of Science ®Google Scholar
• Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011;21:440–6
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004;303:1818–22
   PubMed Web of Science ®Google Scholar
• Duggan ST, Keating GM. Pegylated liposomal doxorubicin: A review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma. Drugs 2011;71:2531–58
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440–9
   PubMed Web of Science ®Google Scholar
• Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870–7
   PubMed Web of Science ®Google Scholar
• Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, de Wiel-Ambagtsheer Ga, van Tiel ST, et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007;67:9455–62
   PubMed Web of Science ®Google Scholar
• Chrastina A, Massey KA, Schnitzer JE. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011;3:421–37
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al.; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study. Lancet Oncol 2010;11:561–70
   PubMed Web of Science ®Google Scholar
• Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978;202:1290–3
   PubMed Web of Science ®Google Scholar
• Diederich CJ, Wootton J, Prakash P, Salgaonkar V, Juang T, Scott S, et al. Catheter-based ultrasound hyperthermia with HDR brachytherapy for treatment of locally advanced cancer of the prostate and cervix. Proc SPIE Int Soc Opt Eng 2011; 7901:79010O. doi: 10.1117/12.876401
   PubMedGoogle Scholar
• Kouloulias V, Triantopoulou S, Vrouvas J, Gennatas K, Ouzounoglou N, Kouvaris J, et al. Combined chemoradiotherapy with local microwave hyperthermia for treatment of T3N0 laryngeal carcinoma: A retrospective study with long-term follow-up. Acta Otorhinolaryngol Ital 2014;34:167–73
   PubMed Web of Science ®Google Scholar
• Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size. Cancer Res. 2000;60:4440–5
   PubMed Web of Science ®Google Scholar
• Li L, ten Hagen TL, Bolkestein M, Gasselhuber A, Yatvin J, van Rhoon GC, et al. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release 2013;167:130–7
   PubMed Web of Science ®Google Scholar
• Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol 2009;64:53–65
   PubMed Web of Science ®Google Scholar
• Li L, ten Hagen TL, Haeri A, Soullié T, Scholten C, Seynhaeve AL, et al. A novel two-step mild hyperthermia for advanced liposomal chemotherapy. J Control Release 2014;174:202–8
   PubMed Web of Science ®Google Scholar
• Staruch RM, Ganguly M, Tannock IF, Hynynen K, Chopra R. Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia 2012;28:776–87
   PubMed Web of Science ®Google Scholar
• Kneidl B, Peller M, Winter G, Lindner LH, Hossann M. Thermosensitive liposomal drug delivery systems: State of the art review. Int J Nanomedicine 2014;9:4387–98
   PubMed Web of Science ®Google Scholar
• Staruch R, Chopra R, Hynynen K. Localised drug release using MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia 2011;27:156–71
   PubMed Web of Science ®Google Scholar
• Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61:3027–32
   PubMed Web of Science ®Google Scholar
• Ping X, Angang D, Xia G, Yinzhu Z, Jia L, Guofeng S, Yazhu C. Improved efficacy of liposomal doxorubicin treatment of superficial tumors by thermotherapy. Technol Cancer Res Treat 2015 Apr 16. pii: 1533034615580441. [Epub ahead of print]
   PubMedGoogle Scholar
• Hildebrandt, B, Wust, P, Ahlers, O, Dieing, A, Sreenivasa, G, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43:33–56
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clin Pharmacokinet 2003;42:419–36
   PubMed Web of Science ®Google Scholar
• Laginha KM, Verwoert S, Charrois GJ, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005;11:6944–9
   PubMed Web of Science ®Google Scholar
• Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 2011;108:9851–6
   PubMed Web of Science ®Google Scholar
• Staruch RM, Hynynen K, Chopra R. Hyperthermia-mediated doxorubicin release from thermosensitive liposomes using MR-HIFU: Therapeutic effect in rabbit Vx2 tumours. Int J Hyperthermia 2015;13:1–16
   Google Scholar